Clinical Trial Update: Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating anti-CD7 CAR-T cells in relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Anti-CD7 CAR-T cells (anti-CD7 chimeric antigen receptor T cells)

Snippet

Sponsor: Stephan Grupp MD PhD | Conditions: T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | Status: RECRUITING